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Abstract  
Autophagy is a catabolic process, which mediates degradation of cellular 
components and has important roles in health and disease. Therefore, small 
molecule modulators of autophagy are in great demand. Herein, we describe 
a phenotypic high-content screen for autophagy inhibitors, which led to the 
discovery of a dimethoxypyridine-based class of autophagy inhibitors, which 
derive from previously reported, natural product-inspired MAP4K4 inhibitors. 
Comprehensive structure-activity relationship studies led to a potent 
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compound, and biological validation experiments indicated that the mode of 
action was upstream or independent of mTOR. 
 
Introduction 
Macroautophagy (hereafter autophagy) is a highly conserved cellular process 
in eukaryotes, which mediates the degradation of cellular components within 
specialised subcellular compartments (autophagosomes).1–3 
Autophagosomes derive from the phagophore, a double membrane structure 
that engulfs cellular components that are to be recycled.  The 
autophagosomes subsequently fuse with lysosomes to form 
autophagolysosomes, in which degradation carried out by lysosomal enzymes 
takes place. This multistep process is tightly regulated by upstream signaling 
and is modulated by growth factors, the concentration of amino acids and the 
energy level of the cell. The purpose of this degradation is not only to 
compensate for a temporary lack of nutrients but also to eliminate 
dispensable, long-lived proteins, protein aggregates and organelles. 
Moreover, autophagy has been linked to microbiological infections and aging. 
Although primarily a protective pathway, autophagy can also be involved in 
cell death. Due to its involvement in these (patho)physiological processes, 
autophagy is an essential mechanism for the development, homeostasis and 
survival of cells.  
 
Autophagy plays a crucial role in the degradation of protein aggregates, which 
cause several neurodegenerative diseases, including Alzheimer’s, 
Huntington’s and Parkinson’s diseases.4–6 Additionally, there is evidence that 
autophagy is involved in the prevention of cancer by degrading toxic 
metabolites in the cell.7,8  However, it is also reported to promote the survival 
of cancer cells under conditions of nutrient deprivation.9–13 Consequently, 
whereas an upregulation of autophagy might serve as a preventative strategy 
against cancer, autophagy inhibition is a potential approach for cancer 
therapy after its onset. Since many unanswered questions remain regarding 
the dual role of autophagy in physiology and pathophysiology, there is a 
strong interest in a deeper understanding of its mechanisms. Selective 
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autophagy modulators are valuable tools to study this process at different 
stages of disease.14–17 In this regard, phenotypic screening offers a useful 
starting point for the identification of new biologically active compounds by 
representing a disease relevant system.18–21  
 
Herein we report the identification and validation of dimethoxypyridine-
containing autophagy inhibitors (DMPs) identified through a phenotypic 
screen. The DMPs were originally synthesised in the context of a biology-
oriented synthesis (BIOS)22,23 effort to synthesise pyridones based on the 
natural product Militarone, which were found to be MAPK inhibitors.24 We 
describe a comprehensive SAR analysis, detailing the requirements for 
activity, in addition to biological validation experiments.  
 
Results 
Phenotypic screening for autophagy inhibitors 
For monitoring and quantifying autophagy, MCF7 cells stably transfected with 
green fluorescent protein tagged light chain 3 (eGFP-LC3) were employed, as 
developed by Balgi et al.25–27Upon autophagy induction, the ubiquitin-like 
cytosolic protein LC3 is conjugated to phosphatidylethanolamine (PE) and 
consequently recruited to the autophagosomal membrane.28 Whereas eGFP-
LC3, and by association the fluorescence signal, is distributed throughout the 
cytoplasm without autophagy induction, eGFP-LC3 accumulates at 
autophagosomes under starvation conditions, which can be visualised as 
fluorescent puncta. The puncta are detected by automated fluorescence 
microscopy and quantified using automated image analysis.25 Incubating the 
cells with Earle’s balanced salt solution (EBSS) induces autophagy through 
amino acid starvation. Chloroquine (CQ), which is also included in the 
starvation medium, inhibits the fusion of autophagosomes with lysosomes, 
preserving eGFP fluorescence by inhibiting its degradation by the 
autolysosomes. This increases the dynamic range of the assay.29  
 
As part of our ongoing programme to identify autophagy inhibitors,30–32 we 
identified a 2,4-dimethoxypyridine (DMP) based compound class, which 
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inhibited starvation-induced autophagy (Figure 1).  These compounds are 
synthetic precursors of a Militarinone-inspired, neuritogenic compound 
collection. The finding that synthetic precursors have different biological 
activity underlines the utility of the BIOS concept.33 We sought to explore the 
SAR of this compound class and optimised them for autophagy inhibition, 
leading to a compound we termed DMP-1 (Figure 1). 
 
 
Figure 1: Structural development of an autophagy inhibitor from a 
neuritogenic MAP-kinase inhibitor. Dimethoxypyridine 2 represents a 
structural precursor for the neuritogenic MAP-kinase inhibitor 1. By varying 
the substitution pattern of 2 and maintaining the alcohol adjacent to the 
pyridine, autophagy inhibitors (including 3) were identified. 
 
Synthesis 
In addition to the 2,4-dimethoxypyridines that were prepared in the original 
study,24 further compounds of this class were synthesised, leading to >200 
analogues (Scheme 1). The synthesis of compounds 5-11 began from 2,4-
dimethoxypyridine, which was reacted with bromine in acetic acid to give the 
versatile precursor 3,5-dibromo-2,4-dimethoxypyridine 4, which was 
subsequently used in the synthesis of most DMP analogues (Scheme 1). 
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Bromine-lithium exchange with s-BuLi, followed by the addition of either an 
isocyanate or aldehyde electrophile, gave the amides 5 and the secondary 
alcohols 7 respectively. Subsequent Suzuki–Miyaura couplings yielded the 
analogues of type 6 and 8. Oxidation of the secondary alcohol of compounds 
7 or 8 with Dess–Martin periodinane or MnO2 gave the ketones 10 and 9 
respectively. In order to access products with different substituents at the 5-
position of the pyridine ring, Buchwald–Hartwig couplings were used to 
access products of type 11.  
 
 
Scheme 1: General scheme for the synthesis of derivatives of DMP-1 and 
other analogues starting from precursor 4. a) s-BuLi, THF, −78 °C, 1 h, then 
R2NCO, −78 °C → rt, overnight; b) R1B(OH)2, Pd(PPh3)4, dppf, Na2CO3, 
PhMe/EtOH, Δ, 16 h; c) s-BuLi, THF, −78°C, 1 h, then R2CHO, −78°C → rt, 
overnight; d)  MnO2, CH2Cl2, rt, 2 d or Dess–Martin periodinane, CH2Cl2, rt, 
2 h; e) R3R4NH, tBuXPhos, Pd2dba3, NaOtBu, PhMe, 80 °C, overnight. dppf = 
1,1’-Bis(diphenylphosphino)ferrocene, THF = tetrahydrofuran, dba = 
dibenzylidineacetone. 
 
Structure activity relationship (SAR) 
SAR was primarily investigated at the R1 and R2 variable groups of the 2,4-
dimethoxypyridines, along with further variation around the pyridine scaffold 
(see later). In each case, generally both the alcohol and ketone analogues at 
position 3 of the parent 2,4-dimethoxypyridines were investigated. Initially, 
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variation at R1 was investigated, whilst R2 was fixed with a 2-naphthalenyl 
substituent (Table 1). Substitution at R1 was found to be crucial for activity, 
and nitrogenous heterocycles bearing hydrophobic substituents provided the 
most active compounds ( 
Table 1, entries 1-4). For the 1-N-benzylpyrazole-substituted analogues 
investigated (Table 1, entries 1, 2, 7 and 9), substitution on the benzyl 
component significantly influenced potency. Phenols exhibited slightly 
reduced potency (Table 1, entries 5-6). Some substituted phenyls were active 
in the same concentration range as the phenols (Table 1, entries 8 and 11-
12), whilst others were inactive (entry 17). However, smaller and/or more 
polar substituents than the 1-N-benzylpyrazole ring system were not sufficient 
for activity ( 
Table 1, entries 14-16 and 19-22). The analogue where the aromatic ring 
substituent at R1 was replaced with a Br (Table 1, entry 18) was inactive. 
 
Table 1: Inhibition of starvation-induced autophagy determined for selected 
analogues with varying R1 substituents. Where no compound number is 
stated and IC50 data is replaced by a dashed line, the compound has not been 
synthesised. IC50 data is provided as the mean ± SD, n ≥ 3. Where no SD is 
given, n = 2.  For a full list of analogues and activities see Supplementary 
Tables 1–6 
 
Entry R1 Alcohol 
Alcohol 
IC50 [µM] 
Ketone 
Ketone 
IC50 [µM] 
1 
 
12 1.3 ± 0.5  ─ 
2 
 
DMP-1 
(3) 
1.9 ± 0.8 13 6.5 ± 3.2 
3 
 
14 2.2 ± 2.4 15 4.1  
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4 
 
16 2.5 ± 0.5 17 3.9 ± 0.4 
5 
 
18 3.8 ± 1.0 19 ─ 
6 
 
20 3.9  21 >10 
7 
 
22 4.4 ± 0.7  ─ 
8 
 
23 4.6 ± 0.6 24 8.8 ± 0.1 
9 
 
25 5.5 ± 1.4  ─ 
10 
 
26 6.5 ± 1.6 27 4.4 ± 1.6 
11 
 
28 6.6 ± 1.0 29 8.3 ± 0.8 
12 
 
30 7.0 ± 0.6 31 7.3 ± 2.1 
13 
 
32 9.2 ± 1.0  ─ 
14 
 
33 >10  ─ 
15 
 
34 >10  ─ 
16 
 
35 >10  ─ 
17 
 
36 >10 37 >10 
18 Br 38 >10 39 >10 
19 
 
40 >10 41 3.0  
20 
 
42 >10  ─ 
21 
 
43 >10 44 4.2  
23 
 
45 >10  ─ 
 
Next, we turned our attention to varying the R2 group of the 2,4-
dimethoxypyridines, whilst keeping the 1-benzyl-1H-pyrazol-4-yl substituent 
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constant at R1. Favourable substituents at R2 were mostly bulky and lipophilic 
(Table 2, entries 1–7), and were linked to the pyridine either by a 
hydroxymethyl group, a ketone, or an amide. The hydroxymethyl group seems 
to be favoured in terms of potency when compared to the carbonyl (Table 2, 
entry 1). This trend was found to be consistent throughout the analogue series 
studied, with the exception of two pairs of compounds (Table 1, entries 20 and 
22). Small, fluorine-containing aromatics retained activity (Table 2, entries 2–
3). Efforts to reduce the size of R2 by replacing the naphthalene ring system in 
the lead compounds (Table 1, entry 1-2) with a phenyl acetylene (Table 2, 
entry 4) led to a slightly less active analogue. Varying the size and orientation 
of R2 with respect to the naphthalene on 3, whilst retaining hydrophobicity 
also reduced the potency, suggesting that there are favored orientations for 
the hydrophobic interactions (Table 2, entries 5–7).  Aromatics substituted 
with non-lipophilic heteroatoms were generally less active (Table 2, entries 8 
and 9). Amides bearing phenyl or benzyl substituents proved to be inactive 
(Table 2, entries 10 and 11). Any further attempts to include more polar 
substituents at R2 was not successful (Supplementary Tables 1–5). 
 
Table 2: Inhibition of starvation-induced autophagy determined for selected 
analogues with variations at R2. Where no compound number is stated and 
IC50 data is replaced by a dashed line, the compound has not been 
synthesised. IC50 data is provided as the mean ± SD, n ≥ 3. Where no SD is 
given, n = 2.  For a full list of analogues and activities see Supplementary 
Tables 1–6. 
 
entry R2 Alcohol 
Alcohol 
IC50 [µM] 
carbonyl 
Carbonyl 
IC50 [µM] 
1 
 
DMP-1 
(3) 
1.9 ± 0.8 46 6.5 ± 3.2 
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2 
 
47 2.2 ± 2.0  ─ 
3 
 
48 2.4 ± 0.6 49 6.4 ± 0.6 
4 
 
50 3.3 ± 2.5  ─ 
5 
 
 ─ 51 4.0 ± 1.0 
6 
 
52 4.2 ± 1.4 53 >10 
7 
 
54 5.5 ± 1.5  ─ 
8 
 
55 5.9 ± 1.8 56 3.5 ± 0.3 
9 
 
57 10 ± 6.0  ─ 
10 
 
 ─ 58 >10 
11 
 
 ─ 59 >10 
 
In final SAR studies, further variations of substituents on and around the 
pyridine ring were investigated. The synthesis of the different scaffold 
variations is detailed in Supplementary Figure 1. The two methoxy groups 
were both required for optimal activity, with the 2-methoxy contributing to a 
greater extent than the 4-methoxy substituent (entries 2–4). The pyridine 
nitrogen was dispensable for activity but was retained, as it was expected to 
increase solubility (Table 3, entry 5). Surprisingly, the presence of a methoxy 
group at R5 rendered the compound inactive (Table 3, entry 6).  
 
Table 3: Inhibition of starvation-induced autophagy determined for selected 
analogues with variation on and around the pyridine ring. IC50 data is provided 
as the mean ± SD, n ≥ 3. For a full list of analogues and activities see 
Supplementary Tables 1–6. 
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Entry Compound R3 R4 R5 X IC50 [µM] 
1 
DMP-1 
(3) 
OMe OMe H N 1.9 ± 0.8 
2 60 H OMe H N 3.7 ± 1.5 
3 61 OMe H H N 6.2 ± 1.2 
4 62 H H H N 6.2 ± 2.2 
5 63 OMe OMe H CH 1.8 ± 0.8 
6 64 H OMe OMe N >10 
 
Overall, we generated a library that allowed us to thoroughly explore the SAR 
around the dimethoxypyridine scaffold (Figure 2). We selected DMP-1 (3) as a 
representative inhibitor to further validate this class of compounds as 
inhibitors of autophagy due to its favourable potency, solubility and ease of 
synthesis. 
 
Figure 2: Summary of the explored SAR of the dimethoxypyridine compound 
class in starvation-induced autophagy.  
 
Biological Validation 
DMP-1 inhibited starvation-induced autophagy potently and dose-
dependently, as assessed by the reduction in LC3 puncta in our primary 
screening assay (Figure 3A and 3B). To further validate DMP-1 as an 
autophagy inhibitor, we studied its effect on the key autophagy markers: LC3 
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lipidation and p62 degradation. After the induction of autophagy, LC3 is 
lipidated with phosphatidylethanolamine to form LC3-II,28 an effect that should 
be reversed by an autophagy inhibitor that does not target autophagosome-
lysosome fusion. DMP-1 inhibited LC3 lipidation dose-dependently as 
assessed by western blot analysis (Figure 3C). p62 (also known as 
sequestome 1) acts as a chaperone to target proteins for degradation by the 
autophagic machinery, where it is also degraded. Autophagy inhibitors inhibit 
the degradation of p62 when autophagy is induced. DMP-1 inhibited the 
degradation of p62, confirming its ability to inhibit autophagic flux (Figure 3C).  
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Figure 3: Phenotypic validation of DMP-1 as an autophagy inhibitor. 
A: Fluorescence microscopy images of the starvation-induced autophagy 
screen for inhibition of eGFP-LC3 accumulation. Fed = DMSO control 
incubated in full media (MEM) as positive control. Starved = autophagy was 
induced by amino acid withdrawal (EBSS). DMP-1 reverts the phenotype in a 
dose dependent manner. Scale bar = 50 µm. B: Dose-dependent inhibition of 
amino acid starvation induced eGFP-LC3 accumulation by DMP-1. Data is 
mean ± SD, n ≥ 3; representative graph shown. C: Inhibition of LC3 lipidation 
and p62 degradation by DMP-1 in MCF7-eGFP-LC3 cells. Starvation-induced 
autophagy induces lipidation of LC3-I to LC3-II and degradation of p62. DMP-
1 inhibits both effects in a dose-dependent manner. n ≥ 3, representative blot 
shown. D and E: DMP-1 induces cell death in starved cells by means of 
apoptosis. D: Treatment of MCF7-eGFP-LC3 cells under starved conditions 
(EBSS) or fed conditions (MEM) with DMP-1. Under starvation conditions 
survival is reduced. Cytotoxicity was assessed by means of a WST-1 assay. 
Data points are mean ± SD, n ≥ 3, representative graphs shown. E: DMP-1 
dose dependently induces apoptosis in starved cells. Apoptosis was assessed 
by using a selective caspase 3/7 probe. The experiment was performed with 
an Incucyte Zoom live-cell imaging device. Noc. = Nocodazole (10 µM). Data 
are presented as a percent of the DMSO control. Data points are mean ± SD, 
n ≥ 3, representative bars shown.  
 
As autophagy is a cytoprotective mechanism that is activated in conditions of 
cellular stress, autophagy inhibition is reported to render cells more sensitive 
to the effects of starvation.34 In line with this expectation, DMP-1 selectively 
inhibited the growth of starved MCF7-eGFP-LC3 cells compared to fed cells 
as assessed by a WST-1 proliferation assay (Figure 3D). It has been reported 
that autophagy inhibition causes cells to die via apoptosis.35 MCF7 cells 
treated with DMP-1 showed apoptotic cell death under fed as well as under 
starved conditions, as assessed by live cell imaging of a caspase 3/7 
selective probe, which releases a DNA intercalating dye that labels the nuclei 
of apoptotic cells (Figure 3E). In order to delineate the mode of action of the 
DMPs further, their ability to inhibit autophagy induced by the pharmacological 
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inhibition of mTOR by Rapamycin was assessed in MCF7-eGFP-LC3 cells. 
Neither DMP-1 nor any of its analogues inhibited Rapamycin-induced 
autophagy, which suggests that they act upstream or independently of mTOR 
(data not shown). 
 
To identify the molecular target(s) of DMP-1, we employed a newly developed 
machine learning approach using random forest technology and the CATS2 
topological pharmacophore descriptors.36,37 The built regression random 
forest models use an ensemble of decision trees to provide a consensus 
affinity value prediction [pAffinity = - log(IC50 or KD)] for a range of >1000 
human drug targets extensively curated from ChEMBL.38 Through these 
models, the cannabinoid receptor 1 (CB1) was predicted as macromolecular 
target for DMP-1 (pAffinity = 6.8) with high confidence. Indeed, testing of 
DMP-1 in a CB1 functional assay (Cerep, France) revealed moderate 
antagonist effect (IC50 = 3.1 ± 0.08 µM; KB = 0.32 µM; Figure 3), yet fully in 
line with our regression model (experimental pAffinity = 6.5). A radioligand 
displacement assay further confirmed binding of DMP-1 to CB1 (IC50 = 4.3 
µM, Ki = 3.2 µM, nHill = 1.1).  
 
 
Figure 3: DMP-1 is a cannabinoid 1 receptor antagonist. Functional assay: 
IC50 = 3.1 ± 0.08 µM; KB = 0.32 µM, n = 2. Control: AM281, IC50 = 28 nM. 
Binding assay: IC50 = 4.3 µM, Ki = 3.2 µM, nHill = 1.1, n = 2. Control: R(+)-
WIN-55,212-2, IC50 = 0.53 µM. 
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CB1 has previously been linked to autophagy,39 and CB1 antagonists have 
been suggested to weakly induce autophagy, which is contradictory to our 
findings. We tested a CB1 antagonist (Rimonabant) and an inverse agonist 
(Ipinabant) for their ability to inhibit starvation-induced autophagy. 
Rimonabant weakly inhibited starvation-induced autophagy (IC50 = 4.1 ± 0.7 
µM), while Ipinabant did not. Considering the fact that both compounds target 
CB1 with nanomolar potency, but only show moderate autophagy-modulating 
capabilities, it is unlikely that the ability of DMP-1 to inhibit autophagy stems 
only from its ability to inhibit CB1. Additionally, DMP-1 was also tested in a full 
kinase panel at Life Technologies (Thermo Fischer). No kinase was inhibited 
more than 30% at a concentration of 5 µM, including the MAP4K4, the target 
of Militarinone derivative 1. Further efforts to elucidate the molecular target(s) 
of DMP-1 are currently ongoing and will be reported in due course.  
 
Conclusion 
We reported the discovery, development and biological validation of 2,4-
dimethoxypyridine-based autophagy inhibitors. This compound class was 
developed from Militarinone-inspired MAP4K4 inhibitors,24 demonstrating the 
versatility of the BIOS principle for the development of biologically active small 
molecules. The most potent compound, DMP-1, inhibited starvation but not 
rapamycin-induced autophagic flux, suggesting that it acts upstream or 
independently of mTOR. Computational target identification correctly identified 
the CB1 receptor as a molecular target of DMP-1, however this could not be 
validated using clinically approved CB1 antagonists or inverse agonists, 
highlighting the great challenge that target ID can pose in phenotypic 
screening campaigns. Nonetheless, DMP-1 and analogues thereof expand 
the toolkit of autophagy inhibitors available to study this highly complex 
process and may provide new starting points for drug discovery programmes 
in cancer or neurodegenerative diseases. 
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